Elevance Health Files 8-K for Regulation FD Disclosure

Ticker: ELV · Form: 8-K · Filed: 2025-03-10T00:00:00.000Z

Sentiment: neutral

Topics: regulation-fd, disclosure

TL;DR

Elevance Health dropped an 8-K for a Reg FD disclosure on 3/10/25 - could be big news.

AI Summary

Elevance Health, Inc. filed an 8-K on March 10, 2025, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of the disclosure, but it is a current report filed as of March 10, 2025.

Why It Matters

This filing indicates Elevance Health is making a public disclosure under Regulation FD, which could contain material information for investors.

Risk Assessment

Risk Level: medium — The filing is a Regulation FD disclosure, which often contains material non-public information that could impact the stock price.

Key Players & Entities

Elevance Health, Inc. (company) — Registrant
Indiana (jurisdiction) — State of incorporation
001-16751 (company_id) — Commission File Number
35-2145715 (company_id) — I.R.S. Employer Identification Number
220 Virginia Ave (address) — Principal executive offices
Indianapolis (city) — Principal executive offices
IN (state) — Principal executive offices
46204 (zip_code) — Principal executive offices
( 833 ) 401-1577 (phone_number) — Registrant's telephone number
Anthem, Inc. (company) — Former company name

FAQ

What is the specific nature of the Regulation FD Disclosure made by Elevance Health?

The provided text of the 8-K filing does not specify the details of the Regulation FD Disclosure.

When was this 8-K filing submitted to the SEC?

The 8-K filing was submitted on March 10, 2025.

What is Elevance Health's principal executive office address?

Elevance Health's principal executive offices are located at 220 Virginia Ave, Indianapolis, IN 46204.

What is Elevance Health's telephone number?

Elevance Health's telephone number is (833) 401-1577.

What was Elevance Health previously known as?

Elevance Health was formerly known as Anthem, Inc., WELLPOINT, INC, and WELLPOINT INC.

From the Filing

0001193125-25-050889.txt : 20250310 0001193125-25-050889.hdr.sgml : 20250310 20250310161717 ACCESSION NUMBER: 0001193125-25-050889 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250310 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20250310 DATE AS OF CHANGE: 20250310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevance Health, Inc. CENTRAL INDEX KEY: 0001156039 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 352145715 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16751 FILM NUMBER: 25723920 BUSINESS ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 BUSINESS PHONE: 8003311476 MAIL ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 FORMER COMPANY: FORMER CONFORMED NAME: Anthem, Inc. DATE OF NAME CHANGE: 20141202 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT, INC DATE OF NAME CHANGE: 20100105 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT INC DATE OF NAME CHANGE: 20041130 8-K 1 d926071d8k.htm 8-K 8-K false 0001156039 0001156039 2025-03-10 2025-03-10     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 10, 2025 Date of Report (Date of earliest event reported)     Elevance Health, Inc. (Exact name of registrant as specified in its charter)       Indiana   001-16751   35-2145715 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification Number) 220 Virginia Ave Indianapolis , IN 46204 (Address of principal executive offices and zip code) ( 833 ) 401-1577   (Registrant’s telephone number, including area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:     ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol   Name of each exchange on which registered Common Stock, Par Value $0.01   ELV   NYSE Indicate by check mark whether the registrant is an emerging growth company as defined Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       Item 7.01 - Regulation FD Disclosure Officers of Elevance Health, Inc. (the “Company”) will speak with investors over the next several weeks. During these meetings, Company officers intend to reaffirm the Company’s shareholders’ earnings guidance for full year 2025 to be $30.40 to $31.10 per diluted share, including approximately $3.75 per diluted share of net unfavorable items. Excluding these items, the Company continues to expect adjusted shareholders’ earnings to be $34.15 to $34.85 per diluted share. In addition, the Company continues to expect 2025 year-end total medical enrollment t